Don't Just Read the News, Understand It.

Published 22 hours ago • loading... • Updated 9 hours ago

Doublet Shows Activity in Rare, Aggressive Kidney Cancer

Summary by MedPage Today

(MedPage Today) -- Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested...

3 Articles

3 Articles

All

Left

Center

1

Right

Reposted by

Anti-Aging, Acupuncture and Health News

Doublet Shows Activity in Rare, Aggressive Kidney Cancer

(MedPage Today) -- Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested...

22 hours ago·New York, United States

Read Full Article

Kidney Cancer: the 7 Most Effective Ways to Prevent This Disease

Discover the main ways to prevent kidney cancer. From quitting smoking to controlling blood pressure

9 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources3

Leaning Left0Leaning Right0Center1Last Updated6 hours agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States 22 hours ago on Wednesday, June 18, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics